Beam Therapeutics Inc. — Fiscal 2021 Form 10-K Summary
Business context and reporting period
Beam is an early-stage biotechnology company developing precision genetic medicines based primarily on DNA base editing, with ex vivo electroporation, in vivo lipid nanoparticle and AAV delivery capabilities. The filing covers the fiscal year ended December 31, 2021; the company has not generated product sales or completed clinical trials.
Lead programs included BEAM-101 and BEAM-102 for sickle cell disease, BEAM-201 for relapsed/refractory T-cell acute lymphoblastic leukemia, and BEAM-301 for glycogen storage disease type Ia. Beam had 341 full-time employees at year-end, including 234 in research and development.
Financial performance and liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| License and collaboration revenue | $51.8 million | $24 thousand | +$51.8 million |
| Research and development expense | $387.1 million | $103.2 million | +$283.9 million |
| General and administrative expense | $57.2 million | $29.6 million | +$27.6 million |
| Loss from operations | $392.5 million | $132.8 million | Loss increased $259.7 million |
| Net loss | $370.6 million | $194.6 million | Loss increased $176.0 million |
| Net loss per share | $5.77 | $4.19 | Loss per share increased |
| Net cash used in operating activities | $66.3 million | $95.7 million | Use decreased $29.5 million |
| Cash used in investing activities | $294.1 million | $100.1 million | Use increased $194.0 million |
| Cash provided by financing activities | $756.1 million | $322.3 million | +$433.8 million |
Cash, cash equivalents and marketable securities totaled $965.6 million at December 31, 2021, compared with approximately $299.7 million at December 31, 2020. Total assets were $1.47 billion and total liabilities were $647.7 million. The company reported an accumulated deficit of $768.3 million.
Operating cash flow benefited from $348.2 million of deferred revenue, primarily associated with the Pfizer and Apellis agreements, and was reduced by a $300.0 million collaboration receivable related to Pfizer. The Pfizer upfront payment was received in January 2022. Investing cash use included $46.8 million of property and equipment purchases and net purchases of marketable securities.
Equipment financing liabilities totaled $5.3 million at year-end. Lease liabilities totaled $142.4 million for existing operating leases. The company also disclosed approximately $69.0 million of estimated undiscounted lease payments for the planned North Carolina manufacturing facility, which had not commenced and was not recorded on the balance sheet at year-end.
Material changes versus the prior comparable period
- Revenue increased substantially due primarily to $50.0 million recognized from the Sana agreement, $1.8 million from the Apellis agreement and immaterial revenue from Verve. No product revenue was generated.
- Research and development expense increased 275%, including a $155.0 million in-process research and development charge from the Guide acquisition, $39.9 million of non-royalty sublicense fees and higher clinical-readiness, manufacturing, personnel and facility costs.
- Beam acquired Guide Therapeutics for approximately $120.0 million in common stock and recorded contingent consideration liabilities with a year-end fair value of $31.4 million. Potential additional Guide milestone payments total up to $320.0 million in common stock.
- Beam raised approximately $757.4 million through common-stock offerings and option exercises, including a $260.0 million private placement and $511.2 million of gross proceeds under its at-the-market program.
- The company issued $30.0 million of common stock to settle success payments owed to Harvard and the Broad Institute. Remaining success payment liabilities totaled $42.2 million at year-end, and additional payments of up to $90.0 million to each institution may be owed.
- Operating losses increased as Beam expanded its platform, advanced BEAM-101 and BEAM-201 toward clinical readiness, initiated IND-enabling work for BEAM-102 and invested in manufacturing and delivery technologies.
Guidance, outlook, commentary and risks
- Management expects continuing operating losses and negative operating cash flows for the foreseeable future and expects to require additional financing. It believes year-end cash, cash equivalents and marketable securities will fund current plans for at least 12 months from the financial statement issuance date.
- Beam planned to enroll the first participant in the BEACON-101 Phase 1/2 trial for BEAM-101 in the second half of 2022.
- The company expected to submit INDs for BEAM-102 and BEAM-201 during the second half of 2022 and to begin IND-enabling studies for BEAM-301 during 2022.
- Beam expected to nominate an additional liver-targeted development candidate and a second CAR-T development candidate during 2022.
- The planned 100,000-square-foot cGMP manufacturing facility in Research Triangle Park, North Carolina was expected to be operational in the first quarter of 2023. Initial clinical manufacturing will continue to rely on contract manufacturers.
- The Pfizer collaboration provides a $300.0 million upfront payment, potential milestones of up to $350.0 million per program for three programs, and royalties. Pfizer may opt into exclusive worldwide licenses, while Beam has a potential co-development and co-commercialization right for one program after Phase 1/2.
- Key risks include the lack of clinical validation for base editing, potential off-target or delayed effects from permanent genetic edits, delivery and manufacturing challenges, regulatory uncertainty, patient enrollment risk, reliance on third parties, intellectual-property disputes and interference proceedings, competition, COVID-19-related disruptions and the need for substantial additional capital.
- The filing identifies no material legal proceedings. Management and Deloitte & Touche LLP concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2021.
Most important facts for investors to verify
- Whether BEAM-101 enters the clinic on schedule and whether FDA clearance and trial enrollment translate into meaningful human safety and efficacy data.
- The timing and outcome of the planned BEAM-102, BEAM-201 and BEAM-301 IND submissions and related IND-enabling studies.
- The pace of cash burn, the recognition of deferred revenue from Pfizer and Apellis, and the timing and terms of future capital raises.
- Progress, cost and commissioning of the North Carolina manufacturing facility, including the disclosed lease commitments.
- The probability, timing and valuation of Guide technology and product milestones, as well as remaining Harvard and Broad Institute success payments.
- Developments in CRISPR, base-editing and delivery-related patent interferences, oppositions and third-party claims.
- Whether preclinical editing efficiency and tolerability are reproduced in clinical studies, particularly given the company’s disclosure that preclinical results may not predict clinical outcomes.